

NORDIC BREAST CANCER MEETING

21-22 SEPTEMBER 2026

PROGRAM Nordic Breast Cancer Meeting 2026

Monday 21 September

10.00-11.00	Registration
11.00-11.15	Welcome to Stockholm and Nordic Breast Cancer Meeting 2026 <i>Group of ten</i>
11.15-11.30	Sponsor talk 1* Gilead Sciences AB Shaping the future for mTNBC (digital) <i>Professor Frederik Marmé, gynaecologic oncologist at the University Hospital Mannheim and the Medical Faculty Mannheim of Heidelberg University, Germany</i>
	Session 1 AI in breast cancer pathology and imaging <i>Moderator Ilse Vejborg, DK & Anne-Vibeke Lænkholm, DK</i>
11.30-11.45	AI enhanced prognostication in breast pathology <i>Eugenia Colon</i>
11.45-12.00	Deep learning-based assessment of residual breast cancer after neoadjuvant treatment predicts outcomes <i>Anne-Vibeke Lænkholm, DK</i>
12.00-12.15	Experience with Implementation of AI in Capital Mammography Screening Program in Denmark <i>Ilse Vejborg, DK</i>
12.15-12.30	Multi-site validation of an image-based breast cancer model for mammography to drive personalized screening <i>Andreas Lauritzen, DK</i>
12.30-12.45	Sponsor talk 2* AstraZeneca/Daiichi-Sankyo A case for Nordic collaboration to facilitate implementation of new treatments <i>Kim Hjorth-Jensen, Disease Area Specialist, AstraZeneca and Lene Andersson, Medical Scientific Lead, Daiichi-Sankyo</i>
12.45-13.45	Lunch & Exhibition
	Session 2 Response guided surgery <i>Moderator Irma Fredriksson, SE</i>
13.45-14.00	Breast surgery after neoadjuvant treatment -pCR-rates, scattered response and residual microcalcification <i>Irma Fredriksson, SE</i>
14.00-14.25	Axillary surgery after neoadjuvant treatment-pCR-rates, response evaluation and de-escalation <i>Jana de Boniface, SE</i>
14.25-14.35	The SENOMAC ULTRA trial <i>Jana de Boniface, SE</i>
14.35-14.45	The T-REX trial <i>Sara Alkner, SE</i>
14.45-15.00	Sponsor talk 3* Eli Lilly Sweden AB (digital) How do we navigate HR+/HER2- breast cancer in the early stage in the era of CDK4/6-inhibitors? <i>Prof. Nadia Harbeck MD, LMU University Hospital, Munich, Germany</i>
15.00-15.30	Coffee & Exhibition
	Session 3 Surveillance and follow-up <i>Moderator Olöf Bjarnadottir, IS</i>

15.30-15.45	Individualized riskbased imaging surveillance after breast cancer <i>Charlotta Wadsten, SE</i>
15.45-16.00	Modern needs-based, PRO-guided follow-up in early breast cancer <i>Hanne Melgaard Nielsen, DK</i>
16.00-16.15	Nordic Perspectives on Breast Cancer Follow-up: What alignes and what diverges? <i>Olöf Bjarnadottir, IS</i>
	Session 4 Ongoing/Planned and clinical research in the Nordic countries <i>Moderator Birgitte Vrou Offersen, DK & Niklas Loman, SE, Minna Tanner, FI</i>
16.15-16.20	Introduction
16.20-16.30	When less is not enough, first results from the DBCG RT Natural Trial <i>Birgitte Vrou Offersen, DK</i>
16.30-16.40	DBCG RT low five, a clinically controlled randomized trial <i>Maja Maraldo, DK</i>
16.40-16.50	Collaborative trials of systemic treatment, the academic perspective <i>Niklas Loman, SE</i>
16.50-17.00	Design and execution of registry-based and pragmatic trials in Oncology <i>Antonios Valachis, SE</i>
17.00-17.15	Industry sponsored clinical trials - the health care providers perspective <i>Minna Tanner, FI</i>
17.15-17.30	Industry sponsored clinical trials - the industry perspective <i>Frida Lundmark from Lif, SE</i>
17.30-18.00	Panel discussion - representatives from the Nordic countries and the pharmaceutical Industry <i>Moderator: Minna Tanner, FI</i>
18.00-19.30	Poster walk
19.30	Bus to Gamla Riksarkivet <i>Departs 19.30 from Elite Hotel Carolina Tower</i>
20.00	Dinner at Gamla Riksarkivet <i>Adress: Birger Jarls Torg 2a, 111 28 Stockholm</i>
Tuesday 22 September	
08.00-08.15	Sponsor talk 4* Exact Sciences – now Abbott From Evidence to Action: Addressing the Need for Personalized Treatment Decisions in Breast Cancer <i>Rabea Foerster, Director, Chief Medical Officer International at Abbott Cancer Diagnostics</i>
08.15-09.00	Keynote lecture The evolution of clinical cancer genetics in breast cancer care <i>Mark Robson, USA</i>
09.00-10.15	Breakout sessions & Coffee
	Session 5 Patient Advocacy in the Nordic countries <i>Moderator Marit Jensen, SE & Camilla Skare, NO</i>
10.15-11.00	Reports from the different nordic countries <i>Eline Rostad, NO</i> <i>Kaisa Martinkauppi-Vanninen, FI</i> <i>Susanne Dieroff Hay, SE</i>
11.00-11.15	Sponsor talk 5* Veracyte The OPTIMA study <i>Hege Oma Ohnstad</i>
	Session 6 Overview and comparison of national guidelines in the Nordic countries - adjustments and personalization of systemic treatment in early and metastatic breast cancer <i>Moderator Bjørn Naume, NO</i>
11.30-12.30	Presentation of a medical oncology survey based on each of the Nordic countries' national group recommendations <i>Bjørn Naume, NO</i>
	Post-neoadjuvant treatment decisions <i>Christina Bjerre DK</i> Lobular breast cancer <i>Egil Støre Blix, NO</i> ADC use <i>Theodoros Foukakis, SE</i> Treatment of HR+HER2- advanced BC after previous use of ET+CDK4/6i <i>Meri Utriainen</i>
12.30-12.40	Close
12.40	Lunch on the go

*Please note that these sessions are not open for patients.